본문 바로가기
KERD
논문KCI 등재

Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease

Donghee Kim|Aijaz Ahmed|Andrew A. Li
거트앤리버 소화기연관학회협의회|2020.03|Gut and Liver|제14권 제2호|pp. 168-178

2

조회

0

다운로드

7

인용

0

참고문헌

키워드

Metabolic syndromeCardiovascular diseaseNonalcoholic steatohepatitis

초록

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease and encompasses a spectrum of pathology from simple steatosis to inflammation and significant fibrosis that leads to cirrhosis. NAFLD and its comorbid conditions extend well beyond the liver. It is a multisystemic clinical disease entity with extrahepatic manifestations such as cardiovascular disease, type 2 diabetes, chronic kidney disease, hypothyroidism, polycystic ovarian syndrome, and psoriasis. Indeed, the most common causes of mortality in subjects with NAFLD are cardiovascular disease, followed by malignancies and then liver-related complications as a distant third. This review focuses on several of the key extrahepatic manifestations of NAFLD and areas for future investigation. Clinicians should learn to screen and initiate treatment for these extrahepatic manifestations in a prompt and timely fashion before they progress to end-organ damage.

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease and encompasses a spectrum of pathology from simple steatosis to inflammation and significant fibrosis that leads to cirrhosis. NAFLD and its comorbid conditions extend well beyond the liver. It is a multisystemic clinical disease entity with extrahepatic manifestations such as cardiovascular disease, type 2 diabetes, chronic kidney disease, hypothyroidism, polycystic ovarian syndrome, and psoriasis. Indeed, the most common causes of mortality in subjects with NAFLD are cardiovascular disease, followed by malignancies and then liver-related complications as a distant third. This review focuses on several of the key extrahepatic manifestations of NAFLD and areas for future investigation. Clinicians should learn to screen and initiate treatment for these extrahepatic manifestations in a prompt and timely fashion before they progress to end-organ damage.

참고문헌 (130)

  1. Williams CD, "Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy : a prospective study", Gastroenterology, 140, pp.124~131 (2011)
  2. Lazo M, "Prevalence of nonalcoholic fatty liver disease in the United States : the Third National Health and Nutrition Examination Survey, 1988-1994", Am J Epidemiol, 178, pp.38~45 (2013)
  3. Vernon G, "Systematic review : the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults", Aliment Pharmacol Ther, 34, pp.274~285 (2011)
  4. Younossi ZM, "Global epidemiology of nonalcoholic fatty liver disease-metaanalytic assessment of prevalence, incidence, and outcomes", Hepatology, 64, pp.73~84 (2016)
  5. Kim D, "Nonalcoholic fatty liver disease and metabolic syndrome", Clin Liver Dis, 22, pp.133~140 (2018)
  6. Adams LA, "The natural history of nonalcoholic fatty liver disease : a population-based cohort study", Gastroenterology, 129, pp.113~121 (2005)
  7. Kim D, "Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States", Hepatology, 57, pp.1357~1365 (2013)
  8. Marchesini G, "Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome", Hepatology, 37, pp.917~923 (2003)
  9. Brunt EM, "Nonalcoholic fatty liver disease(NAFLD)activity score and the histopathologic diagnosis in NAFLD : distinct clinicopathologic meanings", Hepatology, 53, pp.810~820 (2011)
  10. Stepanova M, "Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease : a population-based study", Gut, 59, pp.1410~1415 (2010)
  11. Ma J, "Bi-directional analysis between fatty liver and cardiovascular disease risk factors", J Hepatol, 66, pp.390~397 (2017)
  12. Kwon YM, "Association of nonalcoholic fatty liver disease with components of metabolic syndrome according to body mass index in Korean adults", Am J Gastroenterol, 107, pp.1852~1858 (2012)
  13. Ballestri S, "Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis", J Gastroenterol Hepatol, 31, pp.936~944 (2016)
  14. Machado M, "Hepatic histology in obese patients undergoing bariatric surgery", J Hepatol, 45, pp.600~606 (2006)
  15. Frantzides CT, "Effect of body mass index on nonalcoholic fatty liver disease in patients undergoing minimally invasive bariatric surgery", J Gastrointest Surg, 8, pp.849~855 (2004)
  16. Abrams GA, "Portal fibrosis and hepatic steatosis in morbidly obese subjects : a spectrum of nonalcoholic fatty liver disease", Hepatology, 40, pp.475~483 (2004)
  17. Dallal RM, "Results of laparoscopic gastric bypass in patients with cirrhosis", Obes Surg, 14, pp.47~53 (2004)
  18. Kim D, "Body fat distribution and risk of incident and regressed nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol, 14, pp.132~138 (2016)
  19. Kim D, "Effect of longitudinal changes of body fat on the incidence and regression of nonalcoholic fatty liver disease", Dig Liver Dis, 50, pp.389~395 (2018)
  20. Yu SJ, "Visceral obesity predicts significant fibrosis in patients with nonalcoholic fatty liver disease", Medicine(Baltimore), 94, pp.e2159~ (2015)
  21. Anstee QM, "Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis", Nat Rev Gastroenterol Hepatol, 10, pp.330~344 (2013)
  22. Targher G, "Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients", Diabetes Care, 30, pp.1212~1218 (2007)
  23. Mantovani A, "Nonalcoholic fatty liver disease and risk of incident type 2 diabetes : a meta-analysis", Diabetes Care, 41, pp.372~382 (2018)
  24. Adams LA, "Nonalcoholic fatty liver disease increases risk of death among patients with diabetes : a community-based cohort study", Am J Gastroenterol, 105, pp.1567~1573 (2010)
  25. Targher G, "Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients", Diabetologia, 53, pp.1341~1348 (2010)
  26. Targher G, "Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis", Clin J Am Soc Nephrol, 5, pp.2166~2171 (2010)
  27. Targher G, "Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative", laser-treated retinopathy in type 2 diabetic patients, 2008, pp.51, 444~450
  28. McPherson S, "Evidence of NAFLD progression from steatosis to fibrosingsteatohepatitis using paired biopsies : implications for prognosis and clinical management", J Hepatol, 62, pp.1148~1155 (2015)
  29. Villanova N, "Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease", Hepatology, 42, pp.473~480 (2005)
  30. Sung KC, "Fatty liver, insulin resistance, and features of metabolic syndrome : relationships with coronary artery calcium in 10, 153 people", Diabetes Care, 35, pp.2359~2364 (2012)
  31. Vanni E, "Systemic complications of nonalcoholic fatty liver disease : when the liver is not an innocent bystander", Semin Liver Dis, 35, pp.236~249 (2015)
  32. Arkan MC, "IKK-beta links inflammation to obesity-induced insulin resistance", Nat Med, 11, pp.191~198 (2005)
  33. Fabbrini E, "Metabolically normal obese people are protected from adverse effects following weight gain", J Clin Invest, 125, pp.787~795 (2015)
  34. Goland S, "Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease : echocardiographic and tissue Doppler imaging assessment", J Clin Gastroenterol, 40, pp.949~955 (2006)
  35. Chatrath H, "Dyslipidemia in patients with nonalcoholic fatty liver disease", Semin Liver Dis, 32, pp.22~29 (2012)
  36. Hui JM, "Beyond insulin resistance in NASH: TNF-alpha or adiponectin?", Hepatology, 40, pp.46~54 (2004)
  37. Petta S, "Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease", Aliment Pharmacol Ther, 34, pp.757~766 (2011)
  38. Sirota JC, "Elevated serum uric acid levels are associated with nonalcoholic fatty liver disease independently of metabolic syndrome features in the United States : liver ultrasound data from the National Health and Nutrition Examination Survey", Metabolism, 62, pp.392~399 (2013)
  39. Targher G, "High-sensitivity C-reactive protein, obesity, and subclinical atherosclerosis : implications of JUPITER from the MESA study", Arterioscler Thromb Vasc Biol, 31, pp.1251~1252 (2011)
  40. Targher G, "Relationship between high-sensitivity C-reactive protein levels and liver histology in subjects with non-alcoholic fatty liver disease", J Hepatol, 45, pp.879~881 (2006)
  41. Softic S, "Lipodystrophy due to adipose tissue-specific insulin receptor knockout results in progressive NAFLD", Diabetes, 65, pp.2187~2200 (2016)
  42. Bugianesi E, "Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity", J Clin Endocrinol Metab, 90, pp.3498~3504 (2005)
  43. Kaser S, "Adiponectin and its receptors in non-alcoholic steatohepatitis", Gut, 54, pp.117~121 (2005)
  44. Targher G, "Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease", Clin Endocrinol(Oxf), 64, pp.679~683 (2006)
  45. Yamaji T, "Interaction between adiponectin and leptin influences the risk of colorectal adenoma", Cancer Res, 70, pp.5430~5437 (2010)
  46. Sookoian S, "Circulating levels and hepatic expression of molecular mediators of atherosclerosis in nonalcoholic fatty liver disease", Atherosclerosis, 209, pp.585~591 (2010)
  47. Targher G, "Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome", Semin Thromb Hemost, 35, pp.277~287 (2009)
  48. Wieckowska A, "Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis", Am J Gastroenterol, 103, pp.1372~1379 (2008)
  49. Tilg H, "Adipocytokines : mediators linking adipose tissue, inflammation and immunity", Nat Rev Immunol, 6, pp.772~783 (2006)
  50. Sookoian S, "Liver transcriptional profile of atherosclerosis-related genes in human nonalcoholic fatty liver disease", Atherosclerosis, 218, pp.378~385 (2011)
  51. Weston CJ, "Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis", J Clin Invest, 125, pp.501~520 (2015)
  52. Oni ET, "A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?", Atherosclerosis, 230, pp.258~267 (2013)
  53. Kim HC, "Association between nonalcoholic fatty liver disease and carotid intima-media thickness according to the presence of metabolic syndrome", Atherosclerosis, 204, pp.521~525 (2009)
  54. Brea A, "Nonalcoholic fatty liver disease is associated with carotid atherosclerosis : a case-control study", Arterioscler Thromb Vasc Biol, 25, pp.1045~1050 (2005)
  55. Fracanzani AL, "Carotid artery intimamedia thickness in nonalcoholic fatty liver disease", Am J Med, 121, pp.72~78 (2008)
  56. Sookoian S, "Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis : a systematic review", J Hepatol, 49, pp.600~607 (2008)
  57. Chung GE, "Nonalcoholic fatty liver disease as a risk factor of arterial stiffness measured by the cardioankle vascular index", Medicine(Baltimore), 94, pp.e654~ (2015)
  58. Salvi P, "Increased arterial stiffness in nonalcoholic fatty liver disease : the Cardio-GOOSE study", J Hypertens, 28, pp.1699~1707 (2010)
  59. Lee YJ, "The relationship between arterial stiffness and nonalcoholic fatty liver disease", Dig Dis Sci, 57, pp.196~203 (2012)
  60. Pacifico L, "Functional and morphological vascular changes in pediatric nonalcoholic fatty liver disease", Hepatology, 52, pp.1643~1651 (2010)
  61. Kim D, "Nonalcoholic fatty liver disease is associated with coronary artery calcification", Hepatology, 56, pp.605~613 (2012)
  62. Wong VW, "Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease", Gut, 60, pp.1721~1727 (2011)
  63. Sung KC, "Interrelationship between fatty liver and insulin resistance in the development of type 2 diabetes", J Clin Endocrinol Metab, 96, pp.1093~1097 (2011)
  64. Wong VW, "Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese : a population study using proton-magnetic resonance spectroscopy and transient elastography", Gut, 61, pp.409~415 (2012)
  65. Park HE, "Nonalcoholic fatty liver disease is associated with coronary artery calcification development : a longitudinal study", J Clin Endocrinol Metab, 101, pp.3134~3143 (2016)
  66. Choi SY, "The relation between non-alcoholic fatty liver disease and the risk of coronary heart disease in Koreans", Am J Gastroenterol, 104, pp.1953~1960 (2009)
  67. Targher G, "Nonalcoholic fatty liver disease and risk of incident cardiovascular disease : a meta-analysis", J Hepatol, 65, pp.589~600 (2016)
  68. Ekstedt M, "Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up", Hepatology, 61, pp.1547~1554 (2015)
  69. Vilar-Gomez E, "Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease : a multinational cohort study", Gastroenterology, 155, pp.443~457 (2018)
  70. 안아름, "Non-alcoholic Fatty Liver Disease and Chronic Kidney Disease in Koreans Aged 50 Years or Older", Korean Journal of Family Medicine, 34(3), pp.199~205 (2013), 대한가정의학회
  71. Jia G, "Non-alcoholic fatty liver disease is a risk factor for the development of diabetic nephropathy in patients with type 2 diabetes mellitus", PLoS One, 10, pp.e0142808~ (2015)
  72. Mikolasevic I, "Chronic kidney disease and nonalcoholic Fatty liver disease proven by transient elastography", Kidney Blood Press Res, 37, pp.305~310 (2013)
  73. Pacifico L, "The impact of nonalcoholic fatty liver disease on renal function in children with overweight", obesity, 2016, pp.17, E1218~
  74. Pan LL, "Intrahepatic triglyceride content is independently associated with chronic kidney disease in obese adults : a cross-sectional study", Metabolism, 64, pp.1077~1085 (2015)
  75. Sirota JC, "Association between nonalcoholic liver disease and chronic kidney disease : an ultrasound analysis from NHANES 1988-1994", Am J Nephrol, 36, pp.466~471 (2012)
  76. Xu HW, "High FIB-4 index as an independent risk factor of prevalent chronic kidney disease in patients with nonalcoholic fatty liver disease", Hepatol Int, 10, pp.340~346 (2016)
  77. Yilmaz Y, "Microalbuminuria in nondiabetic patients with nonalcoholic fatty liver disease : association with liver fibrosis", Metabolism, 59, pp.1327~1330 (2010)
  78. Yasui K, "Nonalcoholic steatohepatitis and increased risk of chronic kidney disease", Metabolism, 60, pp.735~739 (2011)
  79. Machado MV, "Impaired renal function in morbid obese patients with nonalcoholic fatty liver disease", Liver Int, 32, pp.241~248 (2012)
  80. Musso G, "Association of nonalcoholic fatty liver disease with chronic kidney disease : a systematic review and meta-analysis", PLoS Med, 11, pp.e1001680~ (2014)
  81. Vilar-Gomez E, "Improvement in liver histology due to lifestyle modification is independently associated with improved kidney function in patients with non-alcoholic steatohepatitis", Aliment Pharmacol Ther, 45, pp.332~344 (2017)
  82. Musso G, "Fatty liver and chronic kidney disease : novel mechanistic insights and therapeutic opportunities", Diabetes Care, 39, pp.1830~1845 (2016)
  83. Chung GE, "Non-alcoholic fatty liver disease across the spectrum of hypothyroidism", J Hepatol, 57, pp.150~156 (2012)
  84. Pagadala MR, "Prevalence of hypothyroidism in nonalcoholic fatty liver disease", Dig Dis Sci, 57, pp.528~534 (2012)
  85. Kim D, "Subclinical hypothyroidism and low-normal thyroid function are associated with nonalcoholic steatohepatitis and fibrosis", Clin Gastroenterol Hepatol, 16, pp.123~131 (2018)
  86. Kim D, "Low-normal thyroid function is associated with advanced fibrosis among adults in the United States", Clin Gastroenterol Hepatol, 17, pp.2379~2381 (2019)
  87. Manka PP, "Thyroid hormone receptor regulates hepatic stellate cell activation", J Hepatol, 66(1 Suppl), pp.S582~ (2017)
  88. triazine-6-carbonitrile(MGL-3196), a highly selective thyroid hormone receptor β agonist in clinical trials for the treatment of dyslipidemia, "J Med Chem", 2014, 3912~3923
  89. Kowalik MA, "Thyroid hormones, thyromimetics and their metabolites in the treatment of liver disease", Front Endocrinol(Lausanne), 9, pp.382~ (2018)
  90. March WA, "The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria", Hum Reprod, 25, pp.544~551 (2010)
  91. Kelley CE, "Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome", World J Gastroenterol, 20, pp.14172~14184 (2014)
  92. Brzozowska MM, "An association between non-alcoholic fatty liver disease and polycystic ovarian syndrome", J Gastroenterol Hepatol, 24, pp.243~247 (2009)
  93. Ramezani-Binabaj M, "Are women with polycystic ovarian syndrome at a high risk of non-alcoholic Fatty liver disease; a metaanalysis", Hepat Mon, 14, pp.e23235~ (2014)
  94. Rocha ALL, "Non-alcoholic fatty liver disease in women with polycystic ovary syndrome : systematic review and meta-analysis", J Endocrinol Invest, 40, pp.1279~1288 (2017)
  95. Wu J, "A potential link between polycystic ovary syndrome and non-alcoholic fatty liver disease : an update meta-analysis", Reprod Health, 15, pp.77~ (2018)
  96. Legro RS, "Detecting insulin resistance in polycystic ovary syndrome : purposes and pitfalls", Obstet Gynecol Surv, 59, pp.141~154 (2004)
  97. Karoli R, "Prevalence of hepatic steatosis in women with polycystic ovary syndrome", J Hum Reprod Sci, 6, pp.9~14 (2013)
  98. Gambarin-Gelwan M, "Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome", Clin Gastroenterol Hepatol, 5, pp.496~501 (2007)
  99. Targher G, "Abnormal serum alanine aminotransferase levels are associated with impaired insulin sensitivity in young women with polycystic ovary syndrome", J Endocrinol Invest, 32, pp.695~700 (2009)
  100. Kim JJ, "Polycystic ovary syndrome with hyperandrogenism as a risk factor for non-obese non-alcoholic fatty liver disease", Aliment Pharmacol Ther, 45, pp.1403~1412 (2017)
  101. Ganzetti G, "Non-alcoholic fatty liver disease and psoriasis : so far, so near", World J Hepatol, 7, pp.315~326 (2015)
  102. Gisondi P, "Psoriasis and the metabolic syndrome", Clin Dermatol, 36, pp.21~28 (2018)
  103. Mallbris L, "Metabolic disorders in patients with psoriasis and psoriatic arthritis", Curr Rheumatol Rep, 8, pp.355~363 (2006)
  104. Roberts KK, "The prevalence of NAFLD and NASH among patients with psoriasis in a tertiary care dermatology and rheumatology clinic", Aliment Pharmacol Ther, 41, pp.293~300 (2015)
  105. van der Voort EA, "Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older : results from a population-based study", J Am Acad Dermatol, 70, pp.517~524 (2014)
  106. Gisondi P, "Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis", J Hepatol, 51, pp.758~764 (2009)
  107. Miele L, "Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis", J Hepatol, 51, pp.778~786 (2009)
  108. Campanati A, "The effect of etanercept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis", J Gastroenterol, 48, pp.839~846 (2013)
  109. Prussick RB, "Nonalcoholic fatty liver disease in patients with psoriasis : a consequence of systemic inflammatory burden", Br J Dermatol, 179, pp.16~29 (2018)
  110. Arnett DK, "2019 ACC", AHA guideline on the primary prevention of cardiovascular disease, 2019, pp.140, e596~e646
  111. Kirwan JP, "The essential role of exercise in the management of type 2 diabetes", Cleve Clin J Med, 84(7Suppl 1), pp.S15~S21 (2017)
  112. VanWagner LB, "Extrahepatic manifestations of nonalcoholic fatty liver disease", Curr Hepatol Rep, 15, pp.75~85 (2016)
  113. Chalasani N, "The diagnosis and management of non-alcoholic fatty liver disease : practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology", Gastroenterology, 142, pp.1592~1609 (2012)
  114. Paulweber B, "A European evidencebased guideline for the prevention of type 2 diabetes", Horm Metab Res 2010;42 Suppl, 42(Suppl 1), pp.S3~36 (2010)
  115. Golay A, "Taking small steps towards targets : perspectives for clinical practice in diabetes, cardiometabolic disorders and beyond", Int J Clin Pract, 67, pp.322~332 (2013)
  116. Shen J, "PNPLA3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease", J Gastroenterol Hepatol, 30, pp.139~146 (2015)
  117. Sevastianova K, "Genetic variation in PNPLA3(adiponutrin)confers sensitivity to weight loss-induced decrease in liver fat in humans", Am J Clin Nutr, 94, pp.104~111 (2011)
  118. Marzuillo P, "Weight loss allows the dissection of the interaction between abdominal fat and PNPLA3(adiponutrin)in the liver damage of obese children", J Hepatol, 59, pp.1143~1144 (2013)
  119. Jensen MD, "2013 AHA", ACC, American Heart Association Task Force on Practice Guidelines and The Obesity Society, pp.Circulation, 2014[DOI]
  120. Zelber-Sagi S, "Long term nutritional intake and the risk for non-alcoholic fatty liver disease(NAFLD) : a population based study", J Hepatol, 47, pp.711~717 (2007)
  121. Ferolla SM, "Dietary approach in the treatment of nonalcoholic fatty liver disease", World J Hepatol, 7, pp.2522~2534 (2015)
  122. Assy N, "Soft drink consumption linked with fatty liver in the absence of traditional risk factors", Can J Gastroenterol, 22, pp.811~816 (2008)
  123. van der Poorten D, "Visceral fat : a key mediator of steatohepatitis in metabolic liver disease", Hepatology, 48, pp.449~457 (2008)
  124. Zelber-Sagi S, "Role of leisure-time physical activity in nonalcoholic fatty liver disease : a population-based study", Hepatology, 48, pp.1791~1798 (2008)
  125. Magkos F, "Exercise and fat accumulation in the human liver", Curr Opin Lipidol, 21, pp.507~517 (2010)
  126. Hallsworth K, "Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss", Gut, 60, pp.1278~1283 (2011)
  127. Bae JC, "Regular exercise is associated with a reduction in the risk of NAFLD and decreased liver enzymes in individuals with NAFLD independent of obesity in Korean adults", PLoS One, 7, pp.e46819~ (2012)
  128. Tamura Y, "Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients", J Clin Endocrinol Metab, 90, pp.3191~3196 (2005)
  129. Kwak MS, "Role of physical activity in nonalcoholic fatty liver disease in terms of visceral obesity and insulin resistance", Liver Int, 35, pp.944~952 (2015)
  130. Kwak MS, "The preventive effect of sustained physical activity on incident nonalcoholic fatty liver disease", Liver Int, 37, pp.919~926 (2017)

관련 논문AI추천

Evaluation and Management of Extrahepatic Manifestations of Nonalcoholic Fatty Liver DiseaseAijaz Ahmed, Donghee Kim, Elizabeth S. Aby, Wijarnpreecha Karn대한간학회 · Clinical and Molecular Hepatology2021 · 제27권 제2호Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver diseaseAijaz Ahmed, Donghee Kim, Peter Konyn대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제1호Nonalcoholic fatty liver disease and non-liver comorbiditiesMindie H. Nguyen, Richie Manikat대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제2호Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in nameCheng Han Ng, Daniel Q. Huang, Mindie H. Nguyen대한간학회 · Clinical and Molecular Hepatology2022 · 제28권 제4호Cardiovascular Risk Is Elevated in Lean Subjects with Nonalcoholic Fatty Liver Disease김혜순, Ahn Sang Hoon, Cha Bong-Soo, Han Eugene, Kang Eun Seok, Kim Beom Kyung, Kim Do Young, Kim Mi Kyung, Kim Seung Up, Kim Yuna, Lee Byung-Wan, Lee Hye Won, Lee Jae Seung, Lee Yong-ho, Park Jun Yong거트앤리버 소화기연관학회협의회 · Gut and Liver2022 · 제16권 제2호Risk factors in nonalcoholic fatty liver disease전대원, Eileen L. Yoon, Eunji Ko대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제1호

이 간행물의 다른 논문 (15건)

Metachronous Gastric Cancer: Another Hurdle for Successful Endoscopic Treatment for Early Gastric Cancer?Moon Won Lee, Gwang Ha Kimpp. 145-147Awareness and Access to Therapy in Hepatitis C Virus Infected Patients, Key Barriers to Eliminate the Virus?Do Young Kimpp. 148-149Robot-Assisted Endoscopic Resection: Current Status and Future DirectionsKhek Yu Ho, Hung Leng Kaanpp. 150-152Stable Gastric Pentadecapeptide BPC 157, Robert’s Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye’s Stress Coping Response: Progress, Achievements, and the FuturePredrag Sikiric, Alenka Boban Blagaic, Ante Tvrdeic, Ki Baik Hahm, Katarina Horvat Pavlov, Andrea Petrovic, Antonio Kokot, Slaven Gojkovic, Ivan Krezic, Domagoj Drmic, Rudolf Rucman, Sven Seiwerthpp. 153-167Potential Strategies in the Prevention of Nonsteroidal Anti-inflammatory Drugs-Associated Adverse Effects in the Lower Gastrointestinal TractChuan-Guo Guo, Wai K. Leungpp. 179-189
원문 보기